Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai² Futures Lab™. The renewed collaboration expands Lōkahi’s growing nationwide network of academic institutions contributing to the identification and evaluation of underdeveloped, overlooked, or strategically deprioritized therapeutic assets. The program functions as a capital-efficient component of Lōkahi’s asset origination and evaluation process while providing students with direct experience addressing real-world biopharmaceutical business challenges.
During its first year, the ai² Futures Lab™ engaged 64 students and identified more than 45 potential acquisition assets. Several of these advanced into active pipeline discussions, demonstrating how the program expands Lōkahi’s sourcing reach and analytical capacity while supporting a disciplined and capital-efficient approach to pipeline development.
“The ai² Futures Lab™ was created to provide Lōkahi with a scalable, capital-efficient process for identifying and evaluating therapeutic assets that may have been overlooked, underdeveloped, or strategically deprioritized,” said Brian Peters, Senior Vice President, ai² Division, Lōkahi Therapeutics™. “In our first year, the participating teams identified notable acquisition assets, with several opportunities advancing into active discussions. That is meaningful early validation of the model and its ability to generate actionable opportunities for Lōkahi.”
As a returning participant, the University of Georgia will continue engaging students in projects focused on therapeutic asset identification, evaluation, and strategic assessment. Their work is structured to produce business-focused recommendations that Lōkahi can review for further diligence, partnership consideration, licensing, or potential acquisition.
The ai² Futures Lab™ is the execution layer of Lōkahi’s broader ai² platform, which combines experienced scientific, commercial, regulatory, and clinical judgment with emerging technologies to support disciplined decision-making. Through the Futures Lab™, that methodology is applied to active therapeutic opportunities rather than simulations or traditional academic case studies.
“Our continued participation reflects the strength of the experience and the value it creates for students seeking to understand how business strategy and healthcare innovation intersect,” said Andrew H. Potter, Director of the Office of University Experiential Learning and Head of the Innovation District’s Student Industry Fellows Program at the University of Georgia. “The ai² Futures Lab™ allows students to apply classroom learning to real-world challenges while developing practical skills that are increasingly important across the life sciences industry.”
The University of Georgia remains part of Lōkahi’s growing nationwide ai² Futures Lab™ network. New university participants generally begin with asset-identification projects and may subsequently expand into specialized business, clinical, technology, legal, or capital-focused tracks. This structure is intended to broaden the network’s analytical capabilities while preserving a consistent focus on real-world asset origination, evaluation, and strategic decision-making, including the Discover, Advance, Monetize framework.
About Lōkahi Therapeutics™
Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit www.lokahithera.com. For more information about the ai² Futures Lab program, please visit www.ai2futureslab.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate,” “believe,” “expect,” “plan,” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations, or otherwise); the ability of Lōkahi Therapeutics™ to identify, evaluate, acquire, and advance therapeutic assets; the ability to maintain and expand academic and institutional partnerships; the ability to successfully integrate acquired assets into the company’s pipeline; general business and economic conditions; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260821440277/en/
Media gallery
